Figure 3. Effects of Co-Treatment with Doxorubicin, 4HT and a mTOR Inhibitor. Panel A.
The effects of adding a constant dose of 50 nM 4HT on the doxorubicin IC50 were examined in MCF7/ΔAkt-1(CA) cells. Panel B. The effects of adding a constant dose of 1 nM rapamycin on the doxorubicin IC50 were examined in MCF7/ΔAkt-1(CA) cells. Panel C. The effects of adding a constant dose of 1 nM rapamycin on the 4HT IC50 were examined in MCF7/ΔAkt-1(CA) cells. The statistical significance was determined by the unpaired t test. Comparisons determined to be significant are indicated with (***). Panel A. The P value between doxorubicin vs. doxorubicin and 50 nM 4HT treatment of MCF7/ΔAkt-1(CA) cells was 0.0001. Panel B. The P value between doxorubicin vs. doxorubicin and 1 nM rapamycin treatment of MCF7/ΔAkt-1(CA) cells was 0.0008. Panel C. The P value between 4HT vs. 4HT and 1 nM rapamycin treatment of MCF7/ΔAkt-1(CA) cells was 0.0001.